Interim Report second quarter 2026

NextCell Pharma AB NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Interim report for the second quarter 2026. The report is available on the company's website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year. Please note that, as of 2025, the Company's financial year corresponds to the calendar year. Second quarter (April 1, 2026-June 30, 2026)* Operating income SEK 3.0 million (1.5) * Net sales SEK 3.0 million (1.5), of which Cellaviva contributed SEK 3.0 million (1.5) * Profit/loss after financial items SEK –11.7 million (-11.2) * Cash and cash equivalents SEK 21.1 million (46.9) * Cashflow from operating activities SEK -11.4 million (-7.5) * Total cashflow SEK -11.2 million (24.8) * Earnings per share* SEK -0.09 (-0.13) * Equity ratio** 74 (85) percent First six months (January 1, 2026-June 30, 2026)* Operating income SEK 5.8 million (4.9) * Net sales SEK 5.7 million (4.8), of which Cellaviva contributed SEK 5.6 million (4.1) * Profit/loss after financial items SEK –22.1 million (-18.7) * Cash and cash equivalents SEK 21.1 million (46.9) * Cashflow from operating activities SEK -19.4 million (-16.5) * Total cashflow SEK -4.9 million (14.2) * Earnings per share* SEK -0.18 (-0.24) * Equity ratio** 74 (85) percent *Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the second quarter: 126,392,959 (83,007,258) shares. The average number of shares for the first six months: 119,597,379 (79,228,053) shares. The number of shares in NextCell as of 30 June 2026: 126,392,959 (111,392,959) shares. **Equity ratio: Shareholders’ equity as a percentage of total assets.